Inventor · disambiguated record
John Park
Also filed as: PARK JOHN · PARK JOHN E · PARK JOHN EDWARD
19 granted patents·24 pending applications·298 citations·filing 1996–2023
94Inventor score
Files withBOEHRINGER INGELHEIM INT19ABLYNX NV7BOEHRINGER INGELHEIM PHARMA3PARK JOHN EDWARD3LUDWIG INST CANCER RES2
Top patents by PatentIndex Score
43 records- 0196US10154990B2Medicaments for the treatment or prevention of fibrotic diseasesBOEHRINGER INGELHEIM INT·Filed 2015·Granted Dec 18, 2018·15 cites·5 claims
- 0294US11208476B2Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLPABLYNX NV·Filed 2021·Granted Dec 28, 2021·12 cites·12 claims
- 0393US8486398B2Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compoundsVAN RYN JOANNE·Filed 2011·Granted Jul 16, 2013·27 cites·31 claims
- 0493US6455677B1FAPα-specific antibody with improved producibilityBOEHRINGER INGELHEIM INT·Filed 1999·Granted Sep 24, 2002·103 cites·19 claims
- 0589US6613879B1FAP-activated anti-tumour compoundsBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Sep 2, 2003·46 cites·14 claims
- 0688US11840566B2Methods of treating asthma with polypeptides targeting IL-13 and TSLPABLYNX NV·Filed 2021·Granted Dec 12, 2023·1 cites·18 claims
- 0788US8337845B2A-beta binding polypeptidesPARK JOHN E·Filed 2011·Granted Dec 25, 2012·18 cites·12 claims
- 0887US9034822B2Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compoundsVAN RYN JOANNE·Filed 2013·Granted May 19, 2015·10 cites·9 claims
- 0985US2023372297A1Medicaments for the treatment or prevention of fibrotic diseasesBOEHRINGER INGELHEIM INT·Filed 2023·Application pending·0 cites
- 1077US2010204211A1Medicaments for the treatment or prevention of fibrotic diseasesBOEHRINGER INGELHEIM INT·Filed 2009·Application pending·0 cites
- 1176US5767242AIsolated dimeric fibroblast activation protein alpha, and uses thereofBOEHRINGER INGELHEIM INT·Filed 1996·Granted Jun 16, 1998·32 cites·4 claims
- 1274US12492248B2Methods of treatment utilizing polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLPABLYNX NV·Filed 2021·Granted Dec 9, 2025·0 cites·17 claims
- 1374US12384840B2Nucleic acids encoding polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLPABLYNX NV·Filed 2021·Granted Aug 12, 2025·0 cites·16 claims
- 1472US2019038600A1Medicaments for the treatment or prevention of fibrotic deiseasesBOEHRINGER INGELHEIM INT·Filed 2018·Application pending·0 cites
- 1571US12453749B2Recombinant rhabdovirus encoding for CCL21BOEHRINGER INGELHEIM INT·Filed 2023·Granted Oct 28, 2025·0 cites·15 claims
- 1671US2020330435A1Medicaments for the treatment or prevention of fibrotic diseasesBOEHRINGER INGELHEIM INT·Filed 2020·Application pending·0 cites
- 1769US2014296217A1Medicaments for the treatment or prevention of fibrotic diseasesPARK JOHN EDWARD·Filed 2014·Application pending·0 cites
- 1868US8679502B2Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising sameTAKADA KENZO·Filed 2008·Granted Mar 25, 2014·2 cites·64 claims
- 1968US8614308B2Nucleic acid molecules encoding A-beta binding polypeptidesPARK JOHN E·Filed 2012·Granted Dec 24, 2013·1 cites·3 claims
- 2067US5965373AIsolated dimeric fibroblast activation protein α, and uses thereofLUDWIG INST CANCER RES·Filed 1997·Granted Oct 12, 1999·20 cites·2 claims
- 2167US2021188965A1Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslpABLYNX NV·Filed 2020·Application pending·0 cites
- 2266US2006142373A1Medicaments for the Treatment or Prevention of Fibrotic DiseasesBOEHRINGER INGELHEIM INT·Filed 2005·Application pending·0 cites
- 2360US11707495B2Recombinant rhabdovirus encoding for CCL21BOEHRINGER INGELHEIM INT·Filed 2020·Granted Jul 25, 2023·0 cites·34 claims
- 2457US6846910B2Isolated proteins containing portions of FAPα and other proteinsLUDWIG INST CANCER RES·Filed 1999·Granted Jan 25, 2005·11 cites·5 claims
- 2556US12509522B2Polypeptides comprising immunoglobulin single variable domains targeting il-13 and OX40LABLYNX NV·Filed 2021·Granted Dec 30, 2025·0 cites·20 claims
- 2656US9211330B2A-beta binding polypeptidesABLYNX NV·Filed 2013·Granted Dec 15, 2015·0 cites·5 claims
- 2756US2009048267A1Medicaments for the treatment or prevention of fibrotic diseasesBOEHRINGER INGELHEIM INT·Filed 2008·Application pending·0 cites
- 2855US2014128409A1Medicaments for the treatment or prevention of fibrotic diseasesPARK JOHN EDWARD·Filed 2014·Application pending·0 cites
- 2954US2003143229A1FAPalpha -specific antibody with improved producibilityBOEHRINGER INGELHEIM INT·Filed 2002·Application pending·0 cites
- 3053US2006148883A1Medicaments for the Treatment or Prevention of Fibrotic DiseasesBOEHRINGER INGELHEIM INT·Filed 2005·Application pending·0 cites
- 3152US2024076689A1Viral vectors and nucleic acids for regulated gene therapyBOEHRINGER INGELHEIM INT·Filed 2021·Application pending·0 cites
- 3251US2004033957A1FAP-activated anti-tumor prodrugsBOEHRINGER INGELHEIM PHARMA·Filed 2003·Application pending·0 cites
- 3350US2006154939A1Medicaments for the Treatment or Prevention of Fibrotic DiseasesBOEHRINGER INGELHEIM INT·Filed 2005·Application pending·0 cites
- 3450US2003211979A1FAP-activated anti-tumor compoundsBOEHRINGER INGELHEIM PHARMA·Filed 2003·Application pending·0 cites
- 3548US2012004202A1Medicaments for the treatment or prevention of fibrotic diseasesPARK JOHN EDWARD·Filed 2011·Application pending·0 cites
- 3646US2015210778A1Anticoagulant antidotesBOEHRINGER INGELHEIM INT·Filed 2015·Application pending·0 cites
- 3746US2003232742A1FAP-activated anti-tumor compoundsFiled 2001·Application pending·0 cites
- 3846US2006030579A1Compounds for the treatment of proliverative processesBOEHRINGER INGELHEIM INT·Filed 2005·Application pending·0 cites
- 3945US2002155565A1FAP-activated anti-tumor compoundsFiled 2001·Application pending·0 cites
- 4045US2014205611A1Monoclonal antibodies that bind to hgm-csf and medical compositions comprising sameBOEHRINGER INGELHEIM INT·Filed 2014·Application pending·0 cites
- 4143US2002099180A1Human FAP-alpha-specific antibodiesFiled 2001·Application pending·0 cites
- 4243US2003055052A1FAP-activated anti-tumor compoundsFiled 2001·Application pending·0 cites
- 4341US2011076238A1Compounds for the treatment of proliferative processesBOEHRINGER INGELHEIM INT·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Park files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →